These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 34043927)

  • 1. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.
    Saini KS; Punie K; Twelves C; Bortini S; de Azambuja E; Anderson S; Criscitiello C; Awada A; Loi S
    Expert Opin Biol Ther; 2021 Jul; 21(7):945-962. PubMed ID: 34043927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer.
    Salifu I; Singh N; Berraondo M; Remon J; Salifu S; Severson E; Quintana A; Peiró S; Ramkissoon S; Vidal L; Chico I; Saini KS
    Cancer Treat Res Commun; 2023; 36():100713. PubMed ID: 37172552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
    McGuinness JE; Kalinsky K
    Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
    Pondé N; Aftimos P; Piccart M
    Curr Treat Options Oncol; 2019 Apr; 20(5):37. PubMed ID: 30931493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.
    Xiao T; Ali S; Mata DGMM; Lohmann AE; Blanchette PS
    Curr Oncol; 2023 Jul; 30(7):6447-6461. PubMed ID: 37504334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
    Nicolò E; Zagami P; Curigliano G
    Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
    Goldenberg DM; Sharkey RM
    Expert Opin Biol Ther; 2020 Aug; 20(8):871-885. PubMed ID: 32301634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the Treatment of Early-Stage Breast Cancer.
    Bhardwaj PV; Abdou YG
    Oncologist; 2023 Oct; 28(10):832-844. PubMed ID: 37597245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
    Parisi C; Mahjoubi L; Gazzah A; Barlesi F
    Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond.
    Barroso-Sousa R; Tolaney SM
    BioDrugs; 2021 Mar; 35(2):159-174. PubMed ID: 33666903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
    Zardavas D
    Expert Opin Investig Drugs; 2022 Jun; 31(6):633-644. PubMed ID: 35451891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
    Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
    Ann Oncol; 2024 Jul; 35(7):607-629. PubMed ID: 38648979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in urothelial cancer: current status and future directions.
    Piombino C; Tonni E; Oltrecolli M; Pirola M; Pipitone S; Baldessari C; Dominici M; Sabbatini R; Vitale MG
    Expert Rev Anticancer Ther; 2023; 23(11):1141-1155. PubMed ID: 37772970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future potential targets of antibody-drug conjugates in breast cancer.
    Corti C; Boscolo Bielo L; Schianca AC; Salimbeni BT; Criscitiello C; Curigliano G
    Breast; 2023 Jun; 69():312-322. PubMed ID: 36996620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacituzumab govitecan: an antibody-drug conjugate.
    Sahota S; Vahdat LT
    Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy.
    Jeong JH; Kim SB
    Breast; 2022 Dec; 66():199-203. PubMed ID: 36327625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer.
    Epaillard N; Bassil J; Pistilli B
    Cancer Treat Rev; 2023 Sep; 119():102597. PubMed ID: 37454577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.